Zydus Lifesciences Limited — Investor Meet, 13-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Zydus Lifesciences reported robust Q2 FY26 with consolidated revenue up 17% YoY to 6120 Cr, EBITDA up 38% to 2020 Cr (32.9% margin), and net profit up 38% to 1260 Cr. Growth drivers included strong US formulations, India branded business, and international markets. Strategic moves included acquiring Comfort Click for consumer wellness and completing Amplitude Surgical's 100% acquisition in MedTech. Positive Saroglitazar trial results for PBC and pipeline launches like CUTX-101 are key. The company plans to raise funds for US specialty and global expansion, maintaining a confident outlook for full-year targets.